MaxCyte, Inc. (MXCT) Cash Flow Statement
MaxCyte, Inc. (MXCT) generated -$23.0M of operating cash flow over the twelve months to 2026-06-30, spent $665000 on capital expenditure and had free cash flow of -$23.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MXCTMaxCyte, Inc.Follow MXCT — free
—
Price chart with a free account
- Market cap
- 144.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -10.7 | -14.8 | -21.7 | -27.6 | -34.4 | -23.0 | |
| Capital expenditure | 3.8 | 18.5 | 3.7 | 1.7 | 1.8 | -0.7 | |
| Free cash flow | -14.5 | -33.3 | -25.4 | -29.3 | -36.2 | -23.6 | |
| Stock-based compensation | 8.0 | 11.8 | 14.0 | 13.1 | 9.2 | — |
USD millions · SEC XBRL
MaxCyte, Inc. — questions
- What is MaxCyte, Inc.'s operating cash flow?
- -$23.0M over the twelve months to 2026-06-30.
- How much does MaxCyte, Inc. spend on capital expenditure?
- $665000 over the twelve months to 2026-06-30.
- What is MaxCyte, Inc.'s free cash flow?
- -$23.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from MaxCyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.